Armata gets $3.7M from US Department of War for phage therapy Phase 3

What's the deal? Armata PharmaceuticalsDealroom has a profile for this one. Try Dealroom → has received $3.7 million in non-dilutive funding from the US Department of WarDealroom has a profile for this one. Try Dealroom → to advance the Phase 3 development of AP-SA02, its lead bacteriophage candidate. The grant is the first tranche earmarked specifically for Phase 3 execution under a previously announced award.

What is AP-SA02? The Los Angeles-based, late clinical-stage biotech is developing AP-SA02, a fixed multi-phage cocktail, as an adjunctive treatment for complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA. The therapy has secured Qualified Infectious Disease Product, Fast Track, and Breakthrough Therapy designations from the FDA.

Follow the money: The new funds come through the Medical Technology Enterprise Consortium and are managed by the Naval Medical Research Command with funding from the Defense Health AgencyDealroom has a profile for this one. Try Dealroom → and Joint Warfighter Medical Research Program. The award follows $28.7 million previously provided, bringing cumulative DoWDealroom has a profile for this one. Try Dealroom → support for the program to roughly $32.4 million.

Why now? Armata plans to start a Phase 3 superiority study in complicated bacteremia in the second half of 2026. Positive Phase 2a results were presented at IDWeek 2025 in October 2025.

What's the endgame? Complicated bacteremia carries substantial mortality in both military and civilian populations. "We view this funding as the first commitment of DoW support for the Phase 3 program," said chief executive officer Deborah Birx, adding that Armata intends to keep working with the department on potential additional support as the study advances.

The signal: At $3.7 million, this is a modest tranche — sitting in the lower tier of disclosed rounds — but it reflects sustained government appetite for phage therapies as antibiotic resistance mounts. The steady, non-dilutive federal backing lets Armata push a pivotal study forward without tapping public markets for equity.

Read more: pr.sandyjournal.com

Image credit: Kornienko et al., Wikimedia Commons (CC BY 4.0)